Tarsus Pharmaceuticals (NASDAQ:TARS) Now Covered by Guggenheim

Guggenheim started coverage on shares of Tarsus Pharmaceuticals (NASDAQ:TARS – Get Rating) in a research note issued on Thursday, The Fly reports. The brokerage set a “buy” rating on the stock.

Separately, HC Wainwright reaffirmed a “buy” rating and set a $40.00 price objective on shares of Tarsus Pharmaceuticals in a research note on Wednesday, March 15th.

Tarsus Pharmaceuticals Stock Performance

Tarsus Pharmaceuticals stock opened at $16.16 on Thursday. The company has a debt-to-equity ratio of 0.14, a current ratio of 15.74 and a quick ratio of 15.74. Tarsus Pharmaceuticals has a fifty-two week low of $11.33 and a fifty-two week high of $19.66. The stock’s fifty day moving average is $13.92 and its two-hundred day moving average is $15.08.

Tarsus Pharmaceuticals (NASDAQ:TARS – Get Rating) last posted its quarterly earnings data on Monday, March 13th. The company reported ($0.49) EPS for the quarter, beating analysts’ consensus estimates of ($0.97) by $0.48. The company had revenue of $10.00 million for the quarter, compared to analyst estimates of $11.67 million. Sell-side analysts forecast that Tarsus Pharmaceuticals will post -4.71 EPS for the current fiscal year.

Insiders Place Their Bets

In other Tarsus Pharmaceuticals news, CEO Bobak R. Azamian sold 4,853 shares of the firm’s stock in a transaction dated Wednesday, March 8th. The stock was sold at an average price of $15.02, for a total value of $72,892.06. Following the sale, the chief executive officer now directly owns 1,089,253 shares of the company’s stock, valued at approximately $16,360,580.06. The sale was disclosed in a filing with the SEC, which can be accessed through this link. In other Tarsus Pharmaceuticals news, CEO Bobak R. Azamian sold 4,853 shares of the firm’s stock in a transaction dated Wednesday, March 8th. The stock was sold at an average price of $15.02, for a total value of $72,892.06. Following the sale, the chief executive officer now directly owns 1,089,253 shares of the company’s stock, valued at approximately $16,360,580.06. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, CEO Bobak R. Azamian sold 8,000 shares of the firm’s stock in a transaction dated Wednesday, May 17th. The stock was sold at an average price of $15.90, for a total value of $127,200.00. Following the completion of the sale, the chief executive officer now directly owns 1,043,106 shares in the company, valued at $16,585,385.40. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 67,430 shares of company stock valued at $987,336. Insiders own 33.08% of the company’s stock.

Hedge Funds Weigh In On Tarsus Pharmaceuticals

Large investors have recently modified their holdings of the company. UBS Group AG raised its holdings in shares of Tarsus Pharmaceuticals by 37.0% in the 1st quarter. UBS Group AG now owns 4,226 shares of the company’s stock worth $71,000 after purchasing an additional 1,142 shares during the period. Public Employees Retirement System of Ohio purchased a new position in shares of Tarsus Pharmaceuticals in the 3rd quarter worth about $94,000. Legal & General Group Plc raised its holdings in shares of Tarsus Pharmaceuticals by 182.9% in the 4th quarter. Legal & General Group Plc now owns 6,903 shares of the company’s stock worth $101,000 after purchasing an additional 4,463 shares during the period. Barclays PLC raised its holdings in shares of Tarsus Pharmaceuticals by 110.5% in the 4th quarter. Barclays PLC now owns 7,918 shares of the company’s stock worth $116,000 after purchasing an additional 4,157 shares during the period. Finally, American International Group Inc. raised its holdings in shares of Tarsus Pharmaceuticals by 102.7% during the 2nd quarter. American International Group Inc. now owns 8,486 shares of the company’s stock valued at $124,000 after buying an additional 4,300 shares during the period. 76.82% of the stock is currently owned by hedge funds and other institutional investors.

About Tarsus Pharmaceuticals

(Get Rating)

Tarsus Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for ophthalmic conditions. Its lead product candidate is TP-03, a novel therapeutic that is in Phase III for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.